Literature DB >> 7074181

Prediction of early relapse after pimozide discontinuation by response to d-amphetamine during pimozide treatment.

D P van Kammen, J P Docherty, W E Bunney.   

Abstract

Thirteen schizophrenic patients underwent a d-amphetamine infusion while being treated with pimozide, an antipsychotic agent and a relatively specific dopamine (DA) blocker. Six patients who showed an acute increase in psychosis with d-amphetamine relapsed within 3 months after pimozide withdrawal. Of the seven patients who did not change in psychosis with d-amphetamine, six did not relapse after pimozide discontinuation (Fisher's exact test, p less than 0.005). Retrospectively, the psychosis-inducing effects of d-amphetamine were found to be predictive of psychotic exacerbation following subsequent pimozide withdrawal. Pimozide failed to block the psychotogenic effects of d-amphetamine in six patients indicating that other mechanisms besides DA may play a role in psychotic decompensation. The d-amphetamine infusion paradigm should be studied further to determine its clinical value for identifying which schizophrenic patients are at risk for relapse after discontinuation of neuroleptic treatment.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7074181

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  7 in total

1.  Myths and mystifications of managed care.

Authors:  J P Docherty
Journal:  J Ment Health Adm       Date:  1990

2.  Desipramine attenuates working memory impairments induced by partial loss of catecholamines in the rat medial prefrontal cortex.

Authors:  S M Clinton; I L Sucharski; J M Finlay
Journal:  Psychopharmacology (Berl)       Date:  2005-11-24       Impact factor: 4.530

Review 3.  New Concepts in Dopamine D2 Receptor Biased Signaling and Implications for Schizophrenia Therapy.

Authors:  Nikhil M Urs; Sean M Peterson; Marc G Caron
Journal:  Biol Psychiatry       Date:  2016-10-19       Impact factor: 13.382

Review 4.  The "two-headed" latent inhibition model of schizophrenia: modeling positive and negative symptoms and their treatment.

Authors:  Ina Weiner
Journal:  Psychopharmacology (Berl)       Date:  2003-02-25       Impact factor: 4.530

5.  Amphetamine response and relapse risk after depot neuroleptic discontinuation.

Authors:  B Angrist; E Peselow; M Rubinstein; A Wolkin; J Rotrosen
Journal:  Psychopharmacology (Berl)       Date:  1985       Impact factor: 4.530

6.  Provocative tests with psychostimulant drugs in schizophrenia.

Authors:  J A Lieberman; J M Kane; J Alvir
Journal:  Psychopharmacology (Berl)       Date:  1987       Impact factor: 4.530

7.  Lithium attenuates the activation-euphoria but not the psychosis induced by d-amphetamine in schizophrenia.

Authors:  D P van Kammen; J P Docherty; S R Marder; J E Rosenblatt; W E Bunney
Journal:  Psychopharmacology (Berl)       Date:  1985       Impact factor: 4.530

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.